Correspondence 0001213900-24-009720 from Actinium Pharmaceuticals, Inc. (ATNM) (CIK 0001388320) (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM) (CIK 0001388320)
Date: Feb. 2, 2024 · CIK: 0001388320 · Accession: 0001213900-24-009720
AI Filing Summary & Sentiment
File numbers found in text: 333-273911
Letter
Actinium Pharmaceuticals, Inc.
100 Park Ave., 23rd Floor
New York, NY 10017
February 2, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Dillon Hagius
Re: Actinium Pharmaceuticals, Inc.
Registration Statement on Form S-3
Originally filed on August 11, 2023, as amended on February 2, 2024
File No. 333-273911 (as amended, the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Actinium Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on February 5, 2024, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.
Very truly yours,
Actinium Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Actinium Pharmaceuticals, Inc.
100 Park Ave., 23rd Floor
New York, NY 10017
February 2, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Dillon Hagius
Re: Actinium Pharmaceuticals, Inc.
Registration Statement on Form S-3
Originally filed on August 11, 2023, as amended on February 2, 2024
File No. 333-273911 (as amended, the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the
Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act
of 1933, as amended, Actinium Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on February 5, 2024,
or as soon thereafter as practicable.
Should any member of the staff
of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention:
Jayun Koo, Esq. at (212) 835-4823.
Very truly yours,
Actinium Pharmaceuticals, Inc.
By:
/s/ Sandesh Seth
Sandesh Seth
Chief Executive Officer
cc: Jayun Koo, Esq., Haynes
and Boone, LLP